FDA Removes Clinical Hold On Juno Therapeutics' Cancer Drug Trial, Shares Up 27%

(RTTNews) - Juno Therapeutics Inc. (JUNO), a biopharmaceutical company focused on treatment of cancer, Tuesday said the U.S. Food and Drug Administration has removed the clinical hold on its mid-stage clinical trial of JCAR015, a cancer drug.

Under the revised protocol, the trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.

The FDA had put the clinical trial on a hold after two patients died last week. The deaths followed the recent addition of fludarabine to the pre-conditioning regimen.

Following the news, shares of Juno surged 27.74% in the after-hours trading.